FOR VETERINARY USE ONLY (US)
A First In Erysipelas
Advantages:
- First with powerful S-PX protein protection to
stand up under the most severe erysipelas challenge
- Delivers protection against Erysipelothrix rhusiopathiae
infection through the growing period
- Immunity to this protein has been proven to correlate with
protection against erisipelas challenge in pigs
- Each batch contains an optimum level of S-PX protein to
ensure high performance in the field
- First erysipelas vaccine containing exclusive
Emunade® adjuvant combined with proven M+Pac®
mycoplasma pneumonia protection
- Mycoplasma pneumonia protection up to 6 months after
vaccination1
- Greater reduction in lung lesion scores vs nonvaccinated
controls (p<0.05)1
- Contains safe and smooth Emunade adjuvant
– Exclusive 3-stage antigen delivery system (ADS3)
– Gentle on sows, pigs
– Fewer overall reactions
– Excellent syringeability — easy to administer
Demonstrated 87% protection against mortality
Significantly lowers the clinical signs of erysipelas
|
|
Click graphic for
Product Detailer
|
|
|
Further Reading (PDFs)
Dr. Robyn Fleck, swine technical services manager for Schering-Plough, explains the devastating losses producers endure because of Erysipelas make M+ Rhusigent for the control of mortality especially important. Listen to Dr. Fleck's observations:
-
"This is the first one that is labeled for both the clinical signs of Erysipelas but also for death due to Erysipelas. Being first to be labeled for the control of mortality is very important because it gives producers confidence that their animals will make it all the way to the slaughter plant without being condemned or without dying from Erysipelas.” <<Listen>>
-
“M+Rhusigen is also the first Erysipelas vaccine with Emunade Adjuvant. And Emunade Adjuvant is Schering-Plough Animal Health’s proprietary dual adjuvant system that is both highly efficacious for disease control, but is also extremely safe and smooth.” <<Listen>>
-
“We vaccinated more than 800 pigs – we did it on four different sites in Missouri, Illinois, Iowa and Minnesota. All of the practitioners concluded that the vaccine was very safe for use in animals and said that they were excited to see this product released.” <<Listen>>
-
“Erysipelas control is really critical because it’s catastrophic and expensive and you can afford a lot of vaccine to cover up what your mortalities would be.” <<Listen>>
-
Read Dr. Fleck's Erysipelas Interview notes
|
SPAH Product Listings
1. Evaluation of stability and duration of immunity of Mycoplasma hyopneumoniae bacterin.
IPVS Congress, Sept. 17-20, 2000, Melbourne, Australia.
 |
 |
|
Product Label.
Name of the veterinary medicinal product:
M+Rhusigen®
Administration and Dosage:
For vaccination of healthy swine. Use aseptic technique.
Vaccinate pigs intramuscularly at 3-4 weeks of age or older with a 2 mL dose followed
by a second 2 mL dose 3-4 weeks later. Duration of immunity to Erysipelothrix
rhusiopathiae has been demonstrated by challenge through 22 weeks of age.
Caution:
For use in swine only. Store at 2° to 7°C (35° to 45°F). Do not freeze. Use
entire contents when first opened. Do not vaccinate within 21 days of slaughter. Transient
local reaction may occur at the injection site. Anaphylactoid reactions may occur after use.
Anitdote:
Epinephrine
Warning:
Extreme caution should be used when injecting oil emulsion vaccines
to avoid injecting your own finger or hand. Accidental injection can cause serious
local reaction. Contact a physician immediately if accidental injection occurs.
Preservatives:
Gentamicin and thimerosal.
|
| |
|
NDC |
|
| 50 doses |
100 mL |
0061-1325-01 |
P17960-10 |
| 125 doses |
250 mL |
0061-1325-02 |
P17961-10 |
| 250 doses |
500 mL |
0061-1325-03 |
P17962-10 |
NAC No.: 10472470
|
Schering-Plough Animal Health Corporation P.O. Box 3182 Union, New Jersey 07083-198 USA
© 2006 Schering-Plough Animal Health Corporation.
|
